Preventing Graft Thrombosis in the Elderly through Development of a Risk Prediction Tool
Preventing Graft Thrombosis in the Elderly through Development of a Risk Prediction Tool
批准号:
10710221
负责人:
Anahita Dua
金额:
$26.62万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-30 至 2024-11-30
关键词:
AddressAgeAmputationAnticoagulantsAnticoagulationArteriesAutomobile DrivingBiological AssayBlood Coagulation FactorBlood PlateletsBlood coagulationBlood flowBlood specimenBypassCessation of lifeChronicClinicalCoagulation ProcessDangerousnessDataData SetDevelopmentElderlyEtiologyEventFibrinolysisGenerationsGoalsHemorrhageHyperactivityImpairmentIncidenceIndividualInterventionIntrinsic factorLifeLimb structureLong-Term Care for ElderlyLower ExtremityMapsMeasuresModelingOperative Surgical ProceduresPatientsPatternPeripheral arterial diseasePharmaceutical PreparationsPilot ProjectsPopulationPostoperative PeriodPrevalenceProceduresResearchRiskRisk FactorsSamplingStentsTestingThrombelastographyThrombinThrombophiliaThrombosisTimeTime trendVascularizationVulnerable PopulationsWhole Bloodagedartery occlusionblood perfusionclinical careclinical decision-makingcohortcombathigh riskimprovedlimb amputationmortalitynovelnovel strategiesolder patientovertreatmentpersonalized risk predictionpoint of carepredictive toolspreventprospectiverevascularization surgeryrisk predictionrisk prediction modelstent thrombosistargeted treatmentthromboticthrombotic complicationstool
中文摘要
旁路移植和/或支架血栓形成导致血液流向下肢的损失是一个主要原因
英文摘要
Bypass graft and/or stent thrombosis resulting in loss of blood flow to the lower extremity is a leading cause of
amputation in elderly patients (aged ≥60 years), with an incidence of up to 17%. These amputated elderly
patients suffer 1-year mortality as high as 50%; hence, preventing graft/stent thrombosis is critical. The most
common etiology driving graft/stent thrombosis is hypercoagulability (increased blood clotting propensity).
Current strategies to prevent graft/stent thrombosis rely on anti-platelet and anticoagulant medications, but
managing thromboprophylaxis in elderly patients is challenging as they have high opposing risks of both life-
threatening thrombosis and hemorrhage; therefore, targeted, timely anticoagulant-prescribing is especially
important. Hypercoagulability in these patients after surgery to revascularize extremities with impaired blood flow
can be transient, so the current standard practice of starting anticoagulation to combat temporary thrombotic
propensity increases the risk of hemorrhage during the months post-procedure. There is presently no way to
accurately predict which elderly patients are at risk of thrombosis at a point in time post-limb revascularization to
guide targeted, safe anticoagulation therapy. Hence, the goal of this proposal is to define objective, individualized
metrics to identify elderly patients at high risk of thrombosis and guide thromboprophylaxis strategies to improve
the care of elderly patients. Our preliminary data reveal that point-of-care coagulation tests can identify transient
elevations of coagulation status that are uniquely amplified among elderly patients who develop graft thrombosis.
Furthermore, whole-blood thromboelastography (TEG) and platelet mapping (PM) identified the onset of
hypercoagulability prior to a thrombotic event. These findings advance beyond prior research by showing that
longitudinally acquiring multiple automated measures (in a single blood sample per time point) of individuals'
coagulation parameters and incorporating them into risk-scoring tools can help predict which elderly patients are
at risk of graft thrombosis, and when they are at highest risk, to improve and long-term clinical care. When
combined with clinical variables, such a tool could enable early, targeted anticoagulant intervention that can
prevent clotting complications, thereby reducing the risks of amputation and death. Based on these novel
findings, we hypothesize that combining longitudinal coagulation assays (TEG/platelet mapping/thrombin
generation) with clinical variables in a risk-prediction model will enable identification of elderly patients who are
risk of graft thrombosis. The aims of this project are to: (1) Identify individual hypercoagulability patterns among
elderly patients at risk of extremity graft/stent thrombosis to delineate hyperactive components of the coagulation
cascade; and (2) Develop and validate a novel and personalized risk prediction tool for extremity graft/stent
thrombosis in elderly patients. The results will yield a novel, individualized risk-prediction tool that can identify
elderly patients at high risk for graft/stent extremity thrombosis and guide clinical decision-making to improve
safe and effective thromboprophylaxis strategies for this vulnerable population.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1161/jaha.122.027790
发表时间:
2023-01-03
期刊:
JOURNAL OF THE AMERICAN HEART ASSOCIATION
影响因子:
5.4
作者:
[Majumdar, Monica, Hall, Ryan P., Feldman, Zachary, Goudot, Guillaume, Sumetsky, Natalie, Jessula, Samuel, Kirshkaln, Amanda, Bellomo, Tiffany, Chang, David, Cardenas, Jessica, Patell, Rushad, Eagleton, Matthew, Dua, Anahita]
通讯作者:
Dua, Anahita
Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease.
阿托伐他汀对周围动脉疾病患者氯吡格雷疗效的影响。
DOI:
10.1016/j.avsg.2023.05.023
发表时间:
2023
期刊:
Annals of vascular surgery
影响因子:
1.5
作者:
[SuarezFerreira,SashaP, Hall,RyanP, Majumdar,Monica, Goudot,Guillaume, Jessula,Samuel, Bellomo,Tiffany, Lee,Ivy, Kukreja,Navi, Parmar,Gaurav, Boada,AnaE, Dua,Anahita]
通讯作者:
Dua,Anahita
Preventing Graft Thrombosis in the Elderly through Development of a Risk Prediction Tool
-
批准号:10590991
-
项目类别:
-
资助金额:$21.0万
-
财政年份:2022
-
负责人:Anahita Dua
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: